CLRB

Cellectar Biosciences, Inc. (NASDAQ:CLRB) is a clinical-stage biopharmaceutical company founded in 2002 and headquartered in Florham Park, New Jersey. The company went public in 2005 and specializes in developing innovative cancer treatments using a proprietary drug delivery platform called phospholipid drug conjugates (PDCs). Cellectar focuses on creating targeted radiopharmaceuticals that can deliver radiation directly to cancer cells while minimizing damage to healthy tissue. The company's lead drug candidate, iopofosine I-131 (CLR 131), is currently in late-stage clinical trials for treating blood cancers, particularly Waldenstrom's macroglobulinemia, and the company is preparing for its first commercial product launch.